Overview

Checkpoint Blockade in COVID-19 Pandemic

Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, controlled, open-label, phase 2 clinical trial
Phase:
Phase 2
Details
Lead Sponsor:
MedSIR
Treatments:
Pembrolizumab